Ten-year survival in 290 patients with endometrial cancer: prognostic factors and therapeutic approach. B r / Obstet Gyrzecol 1983;90:654-61.LA VECCHIA, C., FRANCESCHI, S., PARAZZINI, F., COLOMBO, E., COLOMBO, F., LIBERATI, A. and MANGIONI, C., Ten-year survival in 290 patients...
In Singapore, uterine cancer (including endometrial cancer and other much rarer types of uterine cancers) is the fourth most common cancer detected in women4. It is the most common cancer of the female reproductive organs and is more frequently diagnosed in women who have gone through menopause5...
Within the pelvis, cervical cancer spreads first to parametrial nodes, then to obturator, internal and external iliac nodes. In more advanced disease, common iliac and para-aortic nodes may be involved. In a recent 25-centre ACRIN/GOG study, lymphatic metastases were found in 55 of 161 women...
et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21, 1851–1856 (2010). Article PubMed PubMed Central Google Scholar Park, A. B. et al. Racial disparities in survival among women with endometrial cancer in an equal access system. Gynecol. Oncol...
et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21, 1851–1856 (2010). Article PubMed PubMed Central Google Scholar Park, A. B. et al. Racial disparities in survival among women with endometrial cancer in an equal access system. Gynecol. Oncol...
What is the survival rate for endometrial cancer? The average five-year relative survival rates are based on the stage ofendometrial cancerat the time of diagnosis: Localized (the cancer has not spread beyond the uterine lining): 95%
4、rcinomaA. Endometriod adenocarcinoma 80%90% 5-year survival rate: : 65% the higher histological grade is, the worse prognosis of patient is.B. Adenocarcinoma with squamous differentiation 4%5% adenoacanthoma 腺棘皮癌 adenosquamous carcinoma 腺鳞癌 adenocarcinoma with squamous atypical hyperplasia...
Therefore, one must use caution in inferring that metformin improves survival from endometrial cancer specifically, since it is possible that metformin is decreasing other causes of mortality (e.g. diabetes complications or obesity). Four independent preoperative window of opportunity trials have been ...
The overall prognosis for endometrial cancer is generally good and reflects early presentation of the disease in most cases. The 5-year survival rate for all stages is approximately 80% but varies with tumour grade and depth of myometrial invasion. Survival in stage 1 disease is 85–90% but...
Results of the PORTEC-3 trial (NCT00411138), which assessed adjuvant chemotherapy vs radiotherapy alone for patients with high-risk endometrial cancer, demonstrated that adjuvant chemotherapy did not improve 5-year overall survival (OS). Applying The Cancer Genome Atlas molecular classification findings,...